Cargando…

Kinetics of the Cell Cycle Arrest Biomarkers (TIMP2 and IGFBP7) for the Diagnosis of Acute Kidney Injury in Critically Ill COVID-19 Patients

Background: Acute kidney injury (AKI) is highly prevalent in critical COVID-19 patients. The diagnosis and staging of AKI are based on serum creatinine (sCr) and urinary output criteria, with limitations in the functional markers. New cell-cycle arrest biomarkers [TIMP2]*[IGFBP7] have been proposed...

Descripción completa

Detalles Bibliográficos
Autores principales: Greco, Massimiliano, De Rosa, Silvia, Boehm, Fabian, Spano, Sofia, Aceto, Romina, Voza, Antonio, Reggiani, Francesco, Calatroni, Marta, Castellani, Gianluca, Costantini, Elena, Villa, Gianluca, Cecconi, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857893/
https://www.ncbi.nlm.nih.gov/pubmed/36673127
http://dx.doi.org/10.3390/diagnostics13020317
_version_ 1784873962104160256
author Greco, Massimiliano
De Rosa, Silvia
Boehm, Fabian
Spano, Sofia
Aceto, Romina
Voza, Antonio
Reggiani, Francesco
Calatroni, Marta
Castellani, Gianluca
Costantini, Elena
Villa, Gianluca
Cecconi, Maurizio
author_facet Greco, Massimiliano
De Rosa, Silvia
Boehm, Fabian
Spano, Sofia
Aceto, Romina
Voza, Antonio
Reggiani, Francesco
Calatroni, Marta
Castellani, Gianluca
Costantini, Elena
Villa, Gianluca
Cecconi, Maurizio
author_sort Greco, Massimiliano
collection PubMed
description Background: Acute kidney injury (AKI) is highly prevalent in critical COVID-19 patients. The diagnosis and staging of AKI are based on serum creatinine (sCr) and urinary output criteria, with limitations in the functional markers. New cell-cycle arrest biomarkers [TIMP2]*[IGFBP7] have been proposed for early detection of AKI, but their role in critically ill COVID-19 patients is poorly understood. Methods: We conducted an observational study to assess the performance of [TIMP2]*[IGFBP7] for the detection of AKI in critical COVID-19 patients admitted to our intensive care unit (ICU). We sampled urinary [TIMP2]*[IGFBP7] levels at ICU admission, 12 h, 24 h, and 48 h, and compared the results to the development of AKI, as well as baseline and laboratory data. Results: Forty-one patients were enrolled. The median age was 66 years [57–72] and most were males (85%). Thirteen patients (31.7%) developed no/mild stage AKI, 19 patients (46.3%) moderate AKI, and nine patients (22.0%) severe AKI. The ICU mortality was 29.3%. sCr levels in the Emergency Department or at ICU admission were not significantly different according to AKI stage. [TIMP-2]*[IGFBP-7] urinary levels were elevated in severe AKI at 12 h after ICU admission, but not at ICU admission or 24 h or 48 h after ICU admission. Conclusion: Urinary biomarkers [TIMP-2]*[IGFBP-7] were generally increased in this population with a high prevalence of AKI, and were higher in patients with severe AKI measured at 12 h from ICU admission. Further studies are needed to evaluate the best timing of these biomarkers in this population.
format Online
Article
Text
id pubmed-9857893
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98578932023-01-21 Kinetics of the Cell Cycle Arrest Biomarkers (TIMP2 and IGFBP7) for the Diagnosis of Acute Kidney Injury in Critically Ill COVID-19 Patients Greco, Massimiliano De Rosa, Silvia Boehm, Fabian Spano, Sofia Aceto, Romina Voza, Antonio Reggiani, Francesco Calatroni, Marta Castellani, Gianluca Costantini, Elena Villa, Gianluca Cecconi, Maurizio Diagnostics (Basel) Article Background: Acute kidney injury (AKI) is highly prevalent in critical COVID-19 patients. The diagnosis and staging of AKI are based on serum creatinine (sCr) and urinary output criteria, with limitations in the functional markers. New cell-cycle arrest biomarkers [TIMP2]*[IGFBP7] have been proposed for early detection of AKI, but their role in critically ill COVID-19 patients is poorly understood. Methods: We conducted an observational study to assess the performance of [TIMP2]*[IGFBP7] for the detection of AKI in critical COVID-19 patients admitted to our intensive care unit (ICU). We sampled urinary [TIMP2]*[IGFBP7] levels at ICU admission, 12 h, 24 h, and 48 h, and compared the results to the development of AKI, as well as baseline and laboratory data. Results: Forty-one patients were enrolled. The median age was 66 years [57–72] and most were males (85%). Thirteen patients (31.7%) developed no/mild stage AKI, 19 patients (46.3%) moderate AKI, and nine patients (22.0%) severe AKI. The ICU mortality was 29.3%. sCr levels in the Emergency Department or at ICU admission were not significantly different according to AKI stage. [TIMP-2]*[IGFBP-7] urinary levels were elevated in severe AKI at 12 h after ICU admission, but not at ICU admission or 24 h or 48 h after ICU admission. Conclusion: Urinary biomarkers [TIMP-2]*[IGFBP-7] were generally increased in this population with a high prevalence of AKI, and were higher in patients with severe AKI measured at 12 h from ICU admission. Further studies are needed to evaluate the best timing of these biomarkers in this population. MDPI 2023-01-15 /pmc/articles/PMC9857893/ /pubmed/36673127 http://dx.doi.org/10.3390/diagnostics13020317 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Greco, Massimiliano
De Rosa, Silvia
Boehm, Fabian
Spano, Sofia
Aceto, Romina
Voza, Antonio
Reggiani, Francesco
Calatroni, Marta
Castellani, Gianluca
Costantini, Elena
Villa, Gianluca
Cecconi, Maurizio
Kinetics of the Cell Cycle Arrest Biomarkers (TIMP2 and IGFBP7) for the Diagnosis of Acute Kidney Injury in Critically Ill COVID-19 Patients
title Kinetics of the Cell Cycle Arrest Biomarkers (TIMP2 and IGFBP7) for the Diagnosis of Acute Kidney Injury in Critically Ill COVID-19 Patients
title_full Kinetics of the Cell Cycle Arrest Biomarkers (TIMP2 and IGFBP7) for the Diagnosis of Acute Kidney Injury in Critically Ill COVID-19 Patients
title_fullStr Kinetics of the Cell Cycle Arrest Biomarkers (TIMP2 and IGFBP7) for the Diagnosis of Acute Kidney Injury in Critically Ill COVID-19 Patients
title_full_unstemmed Kinetics of the Cell Cycle Arrest Biomarkers (TIMP2 and IGFBP7) for the Diagnosis of Acute Kidney Injury in Critically Ill COVID-19 Patients
title_short Kinetics of the Cell Cycle Arrest Biomarkers (TIMP2 and IGFBP7) for the Diagnosis of Acute Kidney Injury in Critically Ill COVID-19 Patients
title_sort kinetics of the cell cycle arrest biomarkers (timp2 and igfbp7) for the diagnosis of acute kidney injury in critically ill covid-19 patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857893/
https://www.ncbi.nlm.nih.gov/pubmed/36673127
http://dx.doi.org/10.3390/diagnostics13020317
work_keys_str_mv AT grecomassimiliano kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients
AT derosasilvia kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients
AT boehmfabian kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients
AT spanosofia kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients
AT acetoromina kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients
AT vozaantonio kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients
AT reggianifrancesco kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients
AT calatronimarta kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients
AT castellanigianluca kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients
AT costantinielena kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients
AT villagianluca kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients
AT cecconimaurizio kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients